Clinical Study

An Open-Label, Single-Arm Study To Evaluate The Effectiveness And Safety Of Ocrelizumab In Patients With Early Stage Relapsing Remitting Multiple Scle

Posted Date: May 15, 2019

  • Investigator: Lawrence Goldstick
  • Specialties: Multiple Sclerosis, Neurology
  • Type of Study: Drug

The purpose of this study is to see if ocrelizumab (study drug) will halt the worsening of the signs and symptoms of your early stage MS. Ocrelizumab is a type of drug called a monoclonal antibody. Monoclonal antibodies act like your body?s immune system and attach to certain cells in order to at


You Are Invited To Take Part In A Research Study (Also Known As A Clinical Trial) Of A Drug Called


Multiple Sclerosis, F. Hoffmann-La Roche, Ocrelizumab, Relapse Remitting

For More Information:

Melissa Gilchrist

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.